Researchers at the ICR have identified a promising treatment target for Acute Myeloid Leukaemia
The Institute of Cancer Research shared a post on LinkedIn:
“NEWS: A new target for aggressive leukaemia treatment has been discovered by disrupting genome organisation.
Researchers at the ICR have identified a promising treatment target for Acute Myeloid Leukaemia (AML) by focusing on a protein complex which is crucial for cancer cell growth.
The study reveals that interfering with the NURF complex, particularly the protein BPTF, could slow AML progression, offering potential for new, less harmful therapies.
This groundbreaking discovery, published in The EMBO Journal, was funded by the EU’s Horizon 2020 research and innovation programme, the Kirsten and Freddy Johansen Foundation, NEYE Fonden and The Brain Tumour Charity.
Read more from the ICR.
Learn more in The EMBO Journal.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023